– UK, Guildford – Ergomed plc (LON: ERGO), a company focused on providing specialized services to the pharmaceutical industry, today announced the appointment of Anne Whitaker to its Board as an Independent Non-Executive Director effective on 10 June 2022.
“Anne has an excellent track record and extensive global pharmaceutical industry experience and we are delighted to have her joining the Board. I believe that her global network and deep understanding of the pharmaceutical services industry will support the continued growth and strategic development of Ergomed’s CRO and PV businesses internationally.” said Executive Chairman, Dr. Miroslav Reljanović.
About Anne Whitaker
Anne Whitaker has extensive life sciences industry experience, having worked across the pharmaceutical, biotech, and specialty pharma sectors for the last thirty years in the US and internationally. Anne previously held several senior executive roles at Sanofi, GlaxoSmithKline, Bausch Health Company, and Synta Pharmaceuticals, and most recently, she held the position of CEO, and subsequently Chairperson of Aerami Therapeutics, a private life science company. She has served as a Non-Executive Director at several UK-listed healthcare/pharmaceutical services companies including UDG Healthcare and Vectura Group and is currently on the board of several global biopharmaceutical companies.
Anne Whitaker is recognized as a biopharma industry influencer, advisor, and leader, having received numerous awards from PharmaVoice, WomenInc, and Fierce Pharma. She holds a BSc in Chemistry and Business from the University of North Alabama.
Anne Whitaker said: “I have witnessed Ergomed’s consistent growth in recent years and I am highly excited to be joining a leading provider of specialized services to the pharmaceutical industry. I look forward to working with the Board to continue Ergomed’s growth trajectory as we support customers and patients around the world.”
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance, and medical information. Ergomed’s fast-growing services business includes an industry-leading suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, a full range of high-quality clinical research and trial management services under the Ergomed brand, and mission-critical regulatory compliance and consulting services under the ADAMAS brand.
For more information: https://ergomedplc.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
